



Krystal Biotech to Present at Upcoming Scientific Conferences

April 24, 2025

PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.

Presentation details are outlined below.

American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting

Invited Oral Presentation

- **Title:** HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease
- **Presenter:** Trevor Parry, PhD
- **Date and Time:** May 17, 2025 at 8:50AM CT

2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Poster Presentation

- **Title:** Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study
- **Presenter:** Wen Wee Ma, MD, Enterprise Vice Chair, Research, Cancer Institute, Cleveland Clinic
- **Date and Time:** June 2, 2025 from 1:30PM to 4:30PM CT
- **Poster Session or Category:** Developmental Therapeutics – Immunotherapy
- **Abstract Number:** 2575
- **Poster Bd Number:** 222

Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting

Poster Presentation

- **Title:** Topical application of the HSV-1-based gene therapy vector KB801 results in sustained nerve growth factor expression in wounded murine corneas
- **Presenter:** Haley Cartwright, PhD
- **Date and Time:** May 5, 2025 from 3:00PM to 4:45PM MT
- **Poster Session or Category:** 258 – Preclinical Therapeutics
- **Poster Number:** B0154

Society for Investigative Dermatology (SID) 2025 Annual Meeting

Poster Presentation

- **Title:** Expansion of an HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases
- **Presenter:** Bruce Nmezi, PhD
- **Date and Time:** May 9, 2025 from 4:30PM to 6:00PM PT
- **Poster Session or Category:** Genetic Disease, Gene Regulation, Gene Therapy & Epigenetics
- **Poster Number:** 0554

Additional presentation details will be available to conference attendees. Following completion of each conference, presentation slides or posters, as applicable, will also be available to view online on the Investor section of the Company's [website](#).

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRY5) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK[®] is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [X](#) (formerly Twitter).

CONTACT

Investors and Media:

Stéphane Paquette, PhD

Krystal Biotech

spaquette@krystalbio.com



Source: Krystal Biotech, Inc.